Last update June 24, 2022
Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Main tradenames from several countries containing Zaleplon in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Zaleplon is a pyrazolopyrimidine with sedative properties similar to benzodiazepines. It is used as a hypnotic in the treatment of insomnia Oral administration at bedtime.
It is excreted in non-significant clinical amount into breast milk. (Darwish 1999)
Foods with high fat content (e.g, breast milk) delay absorption by the gut. Its low oral bioavailability decreases the pass of it from the mother's milk to the infant's plasma, except in prematures or in the early neonatal period, when a higher intestinal absorption may occur.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Uguz 2021), especially during the neonatal period and in the event of prematurity.
It is recommended to check for sedation and/or lack of appetite in infants. Bed-sharing (co-sleeping) with the baby is not recommended if this drug are used. (ABM 2020 y 2008, UNICEF 2018, 2017, 2014 y 2013, Landa 2012, UNICEF 2006)
It has been withdrawn from the market in several countries.